Regeneron Files 8-K on Results, Reg FD Disclosure

Ticker: REGN · Form: 8-K · Filed: 2024-01-08T00:00:00.000Z

Sentiment: neutral

Topics: regulation-fd, financial-condition, corporate-disclosure

TL;DR

**Regeneron just dropped an 8-K, signaling new financial info is out; watch for details!**

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose information under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This filing indicates that the company is providing an update on its financial performance or other material non-public information, likely in preparation for an upcoming earnings report or investor event. For investors, this matters because it signals that new financial data or significant operational updates are being made public, which could influence the stock price (REGN) as the market digests this information.

Why It Matters

This filing signals that Regeneron is releasing new financial or operational information, which could impact investor sentiment and the stock's valuation. Investors should look for the specific details of the disclosure to understand the implications.

Risk Assessment

Risk Level: medium — The risk is medium because while the filing itself is procedural, the undisclosed content under Items 2.02 and 7.01 could contain positive or negative news impacting the stock.

Analyst Insight

A smart investor would immediately seek out the full content of the 8-K filing, particularly any exhibits or attachments, to understand the specific financial results or disclosures made under Items 2.02 and 7.01, as these will contain the actual news impacting the company.

Key Players & Entities

FAQ

What specific items did Regeneron Pharmaceuticals, Inc. report under in this 8-K filing?

Regeneron Pharmaceuticals, Inc. reported under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits) in this 8-K filing dated January 8, 2024.

What is the filing date and the date of the earliest event reported for this 8-K?

Both the filing date and the date of the earliest event reported for this 8-K are January 8, 2024.

What is the trading symbol and the exchange where Regeneron's Common Stock is registered?

Regeneron's Common Stock trades under the symbol REGN and is registered on the NASDAQ Global Select Market.

What is Regeneron Pharmaceuticals, Inc.'s business address?

Regeneron Pharmaceuticals, Inc.'s business address is 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707.

What is the significance of Item 7.01 (Regulation FD Disclosure) in this 8-K?

Item 7.01 (Regulation FD Disclosure) indicates that Regeneron is making public material non-public information, ensuring fair and broad disclosure to all investors simultaneously, rather than selectively.

From the Filing

0001104659-24-002037.txt : 20240108 0001104659-24-002037.hdr.sgml : 20240108 20240108063044 ACCESSION NUMBER: 0001104659-24-002037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 24518225 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 8-K 1 tm242296d1_8k.htm FORM 8-K false 0000872589 0000872589 2024-01-08 2024-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): January 8, 2024 ( January 8, 2024 )   REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)   New York (State or other jurisdiction of incorporation)   000-19034   13-3444607 (Commission File Number)   (I.R.S. Employer Identification No.)     777 Old Saw Mill River Road , Tarrytown , New York   10591-6707 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: ( 914 ) 847-7000   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 2.02. Results of Operations and Financial Condition.   On January 8, 2024, at the 42nd Annual J.P. Morgan Healthcare Conference, Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”), and George D. Yancopoulos, M.D., Ph.D., Board Co-Chair, President and Chief Scientific Officer of Regeneron, are providing a corporate update.   The prese

View on Read The Filing